Table 6.
BMI-stratified Cox regression hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between urinary phenol concentrations (μg/g creatinine) and all-cause mortality among the ancillary study sample of LIBCSP women with breast cancer (n=709).
| BMI <25.0 kg/m2(n=316) |
BMI ≥25.0 kg/m2 (n=393) |
PInteraction | |||||
|---|---|---|---|---|---|---|---|
| Biomarker (μ/g creatinine) |
Deaths (n=101) |
Censored (n=215) |
Multivariable- adjusted HR (95% CI)a |
Deaths (n=169) |
Censored (n=224) |
Multivariable- adjusted HR (95% CI)a |
|
| 2,5-dichlorophenol | 0.38 | ||||||
| 0.648-6.41 | 48 | 82 | 1 (Reference) | 57 | 79 | 1 (Reference) | |
| 4.42-20.9 | 22 | 77 | 0.53 (0.32-0.89) | 50 | 67 | 1.20 (0.81-1.78) | |
| 21.0-9,149 | 31 | 56 | 0.80 (0.50-1.27) | 62 | 78 | 0.96 (0.66-1.38) | |
| Ln(2,5-dichlorophenol) | 0.93 (0.82-1.06) | 0.98 (0.90-1.07) | |||||
| Benzophenone-3 | 0.95 | ||||||
| <LOD-4.55 | 35 | 51 | 1 (Reference) | 79 | 74 | 1 (Reference) | |
| 4.71-44.1 | 30 | 74 | 0.82 (0.50-1.37) | 52 | 95 | 0.89 (0.62-1.27) | |
| 44.5-26,184 | 36 | 89 | 0.87 (0.53-1.41) | 38 | 55 | 1.02 (0.68-1.53) | |
| Ln(Benzophenone-3) | 0.98 (0.91-1.06) | 0.99 (0.92-1.06) | |||||
| Bisphenol A | 0.41 | ||||||
| <LOD-1.23 | 36 | 83 | 1 (Reference) | 58 | 81 | 1 (Reference) | |
| 1.24-2.44 | 35 | 70 | 1.16 (0.72-1.87) | 47 | 77 | 0.85 (0.57-1.26) | |
| 2.45-388 | 30 | 62 | 1.29 (0.78-2.12) | 64 | 66 | 1.28 (0.89-1.84) | |
| Ln(Bisphenol A) | 1.05 (0.84-1.32) | 1.17 (0.99-1.37) | |||||
| Triclosan | NDb | ||||||
| <LOD | 48 | 89 | 1 (Reference) | 93 | 103 | 1 (Reference) | |
| LOD-15.9 | 31 | 63 | 1.30 (0.80-2.09) | 40 | 54 | 1.02 (0.70-1.49) | |
| 16.0-1,715 | 22 | 63 | 0.88 (0.52-1.49) | 36 | 67 | 0.75 (0.51-1.11) | |
| Methylparaben | 0.96 | ||||||
| 1.04-73.3 | 26 | 45 | 1 (Reference) | 72 | 79 | 1 (Reference) | |
| 73.7-267 | 29 | 77 | 0.65 (0.37-1.12) | 54 | 81 | 0.78 (0.54-1.12) | |
| 270-3,174 | 46 | 93 | 0.77 (0.47-1.28) | 43 | 64 | 0.74 (0.50-1.09) | |
| Ln(Methylparaben) | 0.93 (0.80-1.08) | 0.90 (0.81-1.00) | |||||
| Propylparaben | 0.55 | ||||||
| <LOD-12.4 | 22 | 42 | 1 (Reference) | 67 | 73 | 1 (Reference) | |
| 12.9-67.7 | 34 | 75 | 1.04 (0.59-1.80) | 60 | 84 | 0.81 (0.57-1.15) | |
| 68.2-3,116 | 45 | 98 | 0.87 (0.51-1.46) | 42 | 67 | 0.62 (0.42-0.92) | |
| Ln(Propylparaben) | 0.96 (0.85-1.07) | 0.92 (0.85-0.99) | |||||
| Butylparaben | NDb | ||||||
| <LOD | 48 | 87 | 1 (Reference) | 104 | 129 | 1 (Reference) | |
| LOD-2.49 | 22 | 58 | 0.89 (0.53-1.49) | 37 | 44 | 1.00 (0.68-1.46) | |
| 2.51-173 | 31 | 70 | 0.83 (0.51-1.32) | 28 | 51 | 0.64 (0.42-0.99) | |
| Σparabensc | 0.82 | ||||||
| 2.57-97.1 | 25 | 43 | 1 (Reference) | 74 | 87 | 1 (Reference) | |
| 100-353 | 29 | 74 | 0.69 (0.40-1.21) | 56 | 72 | 0.90 (0.63-1.28) | |
| 354-3,766 | 47 | 98 | 0.80 (0.49-1.32) | 39 | 65 | 0.70 (0.47-1.03) | |
| Ln(Σparabens) | 0.94 (0.81-1.09) | 0.90 (0.81-0.99) | |||||
CI, confidence interval; ND, not determined; HR, hazard ratio
Long Island Breast Cancer Study Project (LIBCSP) women with breast cancer were diagnosed between August 1, 1996 and July 31, 1997 and monitored for vital status from diagnosis through December 31, 2014.
Adjusted for age at diagnosis (continuous in years), education (<HS/HS graduate, College, and Post-college), menopausal status (pre- vs post-menopausal), hormone replacement therapy use (never vs ever), and parity/lactation history (nulliparous, parous/never lactated, and parous/ever lactated).
Not determined due to high proportions <LOD.
ΣParabens: Creatinine-corrected molar sum of paraben metabolites: methylparaben, propylparaben, and butylparaben (expressed as methylparaben, molecular weight 152).